ASsessment of Adherence TO Medication in AtRIAl Fibrillation - an eMonitoring Drug Dispensing Device Study

Inclusion Criteria: * Female or male patient with age \> 18 years * Patients with atrial fibrillation * Patients initiated, continued on or switched to rivaroxaban for the indication atrial fibrillation with intended lifelong treatment (CHA2 DS2-VASc score ≥ 1). * The patient must agree to the use of the electronic medication adherence monitoring device, the so-called Pilloxa box and need to have a sufficient understanding of the app and functionality in conjunction with the use of the Pilloxa box. * Signed informed consent * No participation in an investigational program with interventions outside of routine clinical practice * No contra-indications according to the local marketing authorization Exclusion Criteria: * Participation in an investigational program with interventions outside of routine clinical practice * Contra-indications according to the local marketing authorization